CAM
MREO

Connacht Asset Management’s Mereo BioPharma MREO Stock Holding History

Connacht Asset Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-213,351
Closed -$341K – 133
2021
Q4 		$341K Buy
+213,351
New +$427K 0.33% 86

Other funds holding MREO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Connacht Asset Management's MREO Position: Q1 2022 in Review

Connacht Asset Management sold out of Mereo BioPharma (MREO) in Q1 2022, closing a stake of 213,351 shares — an estimated $341K sold.

Connacht Asset Management first reported a position in MREO in Q4 2021 and held it in 1 quarter. The position peaked at $341K in Q4 2021. 60 funds tracked by Wall St. Rank hold MREO as of Q1 2022.

  • Connacht Asset Management reported no remaining Mereo BioPharma position as of Q1 2022 after selling out during the quarter.
  • Connacht Asset Management sold 213,351 Mereo BioPharma shares in Q1 2022, an estimated $341K.
  • Connacht Asset Management first reported a position in Mereo BioPharma in Q4 2021 and held it in 1 quarter.
  • Connacht Asset Management's Mereo BioPharma position peaked at $341K in Q4 2021.
  • 60 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2022.

Based on Connacht Asset Management's 13F filing for Q1 2022, filed 16 May 2022.